Clinical trial
Safety and Drug Concentrations of REGN20934 in Adults With Overweight or Obesity
Recruiting now · Phase 1 · 1 countries · Registry ID NCT07594093
Recruiting nowPhase 1Interventional
What this study is about
This study will test a study drug called REGN20934 to see how safe and well tolerated this drug is, as well as how the drug is processed in the body for participants with overweight or obesity. The study is looking at: * What side effects REGN20934 might cause * How much REGN20934 is in the blood at different times * If the body makes antibodies to REGN20934
A promising-looking record is not the same as confirmed eligibility. The study team must review the full criteria and current recruitment status.
Basic eligibility
Age18 Years to 65 Years
SexAll
Healthy volunteersAccepted
ConditionOverweight or Obesity
Full registry criteria
Key Inclusion Criteria: 1. Has a Body Mass Index (BMI) 25 to 35 kg/m\^2 2. Females must be of non-childbearing potential Key Exclusion Criteria: 1. A self-reported change of body weight \>5 kg within approximately 90 days of visit 2 2. History of type 1 or type 2 diabetes 3. History of clinically significant cardiovascular, respiratory, hepatic, renal, gastrointestinal, endocrine, hematological, psychiatric, or neurological disease, as defined in the protocol Note: Other protocol defined inclusion/exclusion criteria apply
Treatments and study arms
REGN20934
Drug
Administered per the protocol
Placebo
Drug
Administered per the protocol
Primary outcomes
Occurrence of Treatment Emergent Adverse Events (TEAEs)Up to 16 weeks
Severity of TEAEsUp to 16 weeks
Study locations
1 locations were listed when this page was built. The first 40 are shown.
California Clinical Trials Medical Group🇺🇸 Glendale, California, United States